Cancers, Vol. 11, Pages 1689: Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice

Cancers, Vol. 11, Pages 1689: Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice Cancers doi: 10.3390/cancers11111689 Authors: Edoardo Giannini Andrea Aglitti Mauro Borzio Martina Gambato Maria Guarino Massimo Iavarone Quirino Lai Giovanni Levi Sandri Fabio Melandro Filomena Morisco Francesca Ponziani Maria Rendina Francesco Russo Rodolfo Sacco Mauro Viganò Alessandro Vitale Franco Trevisani on behalf of the Associazione Italiana per lo Studio del Fegato (AISF) HCC Special Interest Group Despite progress in our understanding of the biology of hepatocellular carcinoma (HCC), this tumour remains difficult-to-cure for several reasons, starting from the particular disease environment where it arises—advanced chronic liver disease—to its heterogeneous clinical and biological behaviour. The advent, and good results, of immunotherapy for cancer called for the evaluation of its potential application also in HCC, where there is evidence of intra-hepatic immune response activation. Several studies advanced our knowledge of immune checkpoints expression in HCC, thus suggesting that immune checkpoint blockade may have a strong rationale even in the treatment of HCC. According to this background, initial studies with tremelimumab, a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor, and n...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research